Adenovir Pharma AB has completed a clinical phase one study of its new drug for the treatment of infectious eye disease. Caused by adenoviruses, millions of people are infected every year by epidemic keratoconjuntivitis (EKC). There are currently no effective treatments.
The study included 48 healthy volunteers: 24 subjects in Part A single dose and 24 subjects in Part B multiple dose and showed that Adenovir Pharma’s drug candidate APD -209 is safe and well tolerated.
Every year millions of people the world over are affected by EKC. Today there is no effective antiviral therapy available. Adenovir Pharma is developing a topical drug for the treatment of EKC. Based on the successful Phase I results, Adenovir Pharma is now planning a Phase II study in Europe.
- To have completed the first study in human is a very important phase for the project. The results show that APD-209 is safe and well tolerated, which is in line with the expectations from preclinical studies. We are now planning a Phase 2a-study in patients with EKC and are actively recruiting potential investigators in the EU, said Björn Dellgren, project leader of Adenovir Pharma.
Pontus Ottosson, CEO of P.U.L.S. (Partners för Utvecklingsinvesteringar inom Life Sciences) one of the larger investors in Adenovir Pharma, said:
- The project has developed very well since its inception and has now completed the first clinical phase - an important milestone demonstrating the high level of quality in the development of this new drug.
- Adenovir Pharma represents yet another P.U.L.S project company successfully developing a new therapy that has the potential to address a significant medical need" said Pontus Ottosson.
Major investors include P.U.L.S. AB, BWG Holding, Länsförsäkringar Skåne, Sparbanksstiftelsen Skånes Riskkapitalstiftelse and Augmenta.
About Epidemic Keratoconjunctivitis (EKC):
External ocular infections caused by adenoviruses are among the most common eye infections worldwide. Conjunctivitis accounts for a large proportion of patient visits to ophthalmologists. Epidemic Keratoconjunctivitis (EKC), which is caused by adenoviruses, is a serious and highly-contagious disease. Globally, EKC affects millions of people every year. EKC occurs sporadically and epidemically and is endemic in many regions. The economic and social costs of community EKC epidemics are high. Work places and public institutions, such as schools and day care centres, must be closed when the outbreak of an EKC epidemic is detected. Many productive hours are lost each year as a consequence of the disease. EKC is recognized as a major health problem in affected regions. A pharmaceutical therapy that can be used both to treat EKC and to prevent the spread of infection is highly desirable for affected patients, for those who come into contact with such patients, and for treating physicians. Currently, there are no approved treatments. Patients with EKC receive no medical therapy other than for symptomatic relief.
About Adenovir Pharma AB
Adenovir Pharma is a project company of the life science incubator P.U.L.S. AB, based in Helsingborg, Sweden (www.pulsinvest.se). Adenovir Pharma is developing proprietary technology for new anti-viral pharmaceutical solutions useful in the treatment of infectious eye diseases. The initial development was carried out by Professors Olov Sterner and Ulf Ellervik at Lund University, Department of Organic Chemistry, in collaboration with researchers at Umeå University, along with P.U.L.S. and external service providers specialized in pharmaceutical development. The importance of the research carried out at Umeå University on adenovirus receptor molecules that is the basis for the development of the new drug is highlighted in publications in the prestigious journal Nature Medicine and in the equally high-ranking journal Nature Reviews Drug Discovery. Adenovir Pharma is developing a new drug in the form of eye drops for the treatment of EKC. For more information visit www.adenovir.com.
For more information, please contact:
Partners for Development investments in Life Sciences, P.U.L.S. AB [PULS] was founded in 2002. PULS acts as an incubator and investor for early projects within life science, mostly drug development and has so far started seven project companies.
PULS consist of an operational management team and twenty partners with long experience in life sciences and competence through the whole value chain, from R&D to commercialisation. The business model for PULS is to engage early with innovators to attain an optimal IP platform and high quality development throughout the project.